A new micromethod for the in vitro detection of antiplatelet antibodies: C-FDA thrombocytotoxicity.
A new microtechnique, C-FDA, for the in vitro detection of antiplatelet antibodies, is described. This technique is faster and simpler than either 51Cr thrombocytotoxicity or immunofluorescence (IF). C-FDA is more sensitive than 51Cr for all (anti-HLA, --P1A1, ABO, drug-related, and ITP-related) antibodies tested. Although IF was more sensitive for many types of antibodies, C-FDA was as good or better a clinical test method for all drug-related and isoimmune neonatal thrombocytopenia patient sera tested. Preliminary data also suggest that this method detects possible new non-HLA, non-ABO, nonP1A1 platelet antigens.
D000017:ABO Blood-Group System; D000906:Antibodies; D001792:Blood Platelets / Q000276:immunology*; D002860:Chromium Radioisotopes; D003601:Cytotoxicity Tests, Immunologic / Q000379:methods; D000939:Epitopes; D005188:False Negative Reactions; D005189:False Positive Reactions; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D008297:Male; D013921:Thrombocytopenia / Q000276:immunology
D000017:ABO Blood-Group System; D000906:Antibodies; D002860:Chromium Radioisotopes; D000939:Epitopes